A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin for the prevention of stroke and systemic embolic events (SEE) in patients with atrial fibrillation (ASSURE-AF)
Latest Information Update: 16 Sep 2024
At a glance
- Drugs AZD 0837 (Primary) ; Warfarin
- Indications Embolism; Stroke
- Focus Registrational; Therapeutic Use
- Acronyms ASSURE-AF
- Sponsors AstraZeneca
Most Recent Events
- 14 Sep 2024 This trial has been discontinued in Hungary, according to European Clinical Trials Database record.
- 27 Jun 2012 Additional location (Slovakia) added as reported by European Clinical Trials Database.
- 07 Jul 2011 New trial record